John Sanders

[John Sanders @sande31041]

@DonaldJTrumpJr just watched the Jason Hairston video. Hit me hard. Learned to find true freedom in the outdoors at the age of 42. What an amazing story and hunt. For anyone who hasn’t seen the short about Jason Hariston in memorial, and who DTJR is, you have to watch. That Doll sheep hunt they did is one of the hardest you will ever see. My arctic trip this summer changed my life.

[Tara LaRosa @TaraLaRosa]

Greatest new song to come out of the World Cup! ⚽️❤️🇺🇸 Welcome To The Land Of The Free!🇺🇸❤️⚽️

[John Sanders @sande31041]

@SawyerMerritt @dbatura and the team at X Money have hit this one out of the park. Can’t wait for my invite.

I have purchased many items from X users that were done through other payment channels. Doing it here on X will be amazing.

[ASTS Investors 🅰️ @ASTS_Investors]

AST SPACEMOBILE SELECTED AS WINNER OF J-LEO 🚀

This means they are entitled to $1bn in funding across 3 years to build out a sovereign solution.

Amazing news for the company 🔥

$ASTS

[John Sanders @sande31041]

@ThrillaRilla369 Atilla from Atilla the Hun

[CapexAndChill @CapexAndChill]

So the market fears that AI labs like OpenAI and Anthropic will render $PLTR's enterprise software obsolete.

When asked if Anthropic is a competitor, Karp said that most of the capabilities frontier models discuss in public are currently running on Palantir. At its current scale, Palantir acts as the underlying infra for these AI labs, functioning as a 'nation state' in the ecosystem.

Unlike LLMs, Karp says high-end enterprises such as defense, aerospace, manufacturing require deterministic execution where AI errors are catastrophic. Commercial enterprises are becoming disillusioned with frontier AI labs because raw models lack the capacity to handle strict security, data integration, and ontology, leaving them almost useless for complex corporate infra.

[Chris @StonkChris]

One of my very close friends, who I know personally, has absolutely crushed the markets over the past decade.

He has a rare ability to blend value, dividend, and growth investing, and was early on names like $AMZN, $GOOGL, $META, $MSFT, $HOOD, $INTC, $MPC, and $RTX, buying many of them 10+ years ago.

He's also a fellow engineer and one of the sharpest investors I know.

I've been telling him for years to start sharing his ideas publicly, and he's finally giving X a shot.

If you're looking for thoughtful, long-term investing insights, give him a follow: @InvestorIntelx

[John Sanders @sande31041]

@vz921 @TradexWhisperer @TradexWhisperer BINGO! Not sure why so few others see this. Private data is incredibly more valuable for LLM models than all of the public consumable data that rinses and repeats.

[American Rare Earths Limited (ASX: ARR) @ARRLimited]

@ARRLimited commences 2026 drilling at Halleck Creek to support its DFS program.

The campaign includes approximately 3,050m of HQ core drilling across 19 holes targeting higher-grade mineralisation, resource upgrades and additional metallurgical and geotechnical workstreams.
ASX Announcement: https://t.co/6fT4Ed6KxT

ASX: ARR | OTCQX: ARRNF | ADR: AMRRY

[John Sanders @sande31041]

@Birddog187 @ScienceFocusonX @grok Yes it’s made by Lenz Therapeutics

[ScienceFocus @ScienceFocusonX]

Reading glasses might be done.

The FDA just approved a once-daily eye drop called VIZZ that sharpens near vision in about 30 minutes and keeps it sharp for up to 10 hours.

One drop. Each eye. Per day.

That's it.

The active ingredient is aceclidine, a compound first used back in 1975 to treat glaucoma. Scientists figured out it could be repurposed to gently shrink the pupil, creating a "pinhole effect" that pulls close-up text back into focus, the same trick your eye does when you squint.

Unlike Vuity, the 2021 drop that came before it, VIZZ doesn't mess with your focusing muscles. So no blurry distance vision. No brow ache. No weird zoom effect.

It was tested across more than 30,000 treatment days with no major complications.

Cost is roughly $2 a day.

This matters because presbyopia, the age-related slide that hits most people between 40 and 45, already affects more than 120 million Americans. By 2030, the World Health Organization expects around 2 billion people worldwide to have it.

LENZ Therapeutics, the maker, started rolling out samples in October.

The squint era is ending.

Source: Ynetnews, FOX 26 Houston, Yahoo News

[Serenity @aleabitoreddit]

$SIVE is the largest beneficiary of brand new events this weekend:

1. Sivers new NASDAQ index inclusion (OMX Stockholm):

Both Vanguard and Blackrock are new passive inflows.

With ~$60M+ pure buying pressure inflow, into existing float, together with MSCI next week.

2. US Gov and Sweden sign agreement for joint tech collaboration.

$SIVE is one of the few CHIPS act recipients, and especially in Sweden.

And if you don’t remember, they received another $6.6M CHIPS act award last week.

Making $SIVE heavily supported + critical to the US government.
-

TLDR: New passive institutional inflow from your largest US institutions like Blackrock/Vanguard.

Compounded with US government backing into $SIVE. Over the weekend.

Beneficial for fundamentals (revenue/TAM from Pentagon supply chains) and inflow from Blackrock/Vanguard/MSCI/NASDAQ.

Extremely bullish.

[John Sanders @sande31041]

Are you referring to the $NASA etf and the shares it holds or for what $SATS individually owns?

For $SATS they have direct “private” equity ownership through a transaction completed in 2025 with SPCX (2-3%)

Whereas $NASA is in indirect through an SPV. Thus, can be diluted via inflows. But not public yet.

So higher direct ownership via $SATS, but $NASA provides exposure plus upside to the other Space companies.

I’m personally in both. NFA

[John Sanders @sande31041]

@EversForgeworks They are beautiful. Can’t wait for mine to arrive!